Share Twitter LinkedIn Facebook Email Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations at Annual Meeting 2018.
Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform Acute Myelogenous Leukemia 1 Min Read
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
